With a new wave of Covid-19 infections fueled by the Delta variant striking countries worldwide, disease experts are scrambling to learn whether the latest version of coronavirus is making people – mainly the unvaccinated – sicker than before.

Toronto-based biotech Deep Genomics landed $180 million in the company’s oversubscribed Series C.

EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, announced the acquisition of Accelera Canada and its partner companies Patient Access Solutions, Podium Strategic Partners Inc. and Advocacy Solutions.

In a roundup of scientific studies on the novel coronavirus, new findings shed light on why chronic lung diseases that block the airways increase patients’ risks for severe Covid-19 and researchers say the blood disorder anemia should probably be added to the list of risk factors for poorer Covid-19 outcomes.

Resverlogix Corp. announced a partnership to support planned commercialization of apabetalone in the United States, Canada (where authorization has been granted to conduct clinical studies of apabetalone for COVID-19) and/or potentially expanding to additional global markets, as Emergency Use Authorization and/or a New Drug Application or equivalent is issued or approved. In preparation for launch, Resverlogix will utilize EVERSANA’s fully integrated commercialization services that include market access, agency services, clinical and commercial field teams, medical science liaisons, channel management, patient services, health economics and outcomes research, and compliance, with each service optimized by data and predictive analytics.  

While the United States, Canada and Mexico are reporting overall reductions in Covid-19 cases and deaths, new infections are increasing in the rest of the Americas, Pan American Health Organization (PAHO) Director Carissa Etienne said.

The U.S. Centers for Disease Control and Prevention (CDC) said on May 7 that U.S.-bound international air travelers can meet Covid-19 entry requirements using certain self-administered tests.

Studies have concluded that chatbots have the potential in treating mental health issues and could be used as an effective tool for delivering cognitive behavioral therapy.

The Canadian Down Syndrome Society (CDSS) is partnering with Dr. Dan Gordon and his research team from Anglia Ruskin University and with Dr. Michael Merzenich and his team from BrainHQ to launch a research study and awareness campaign to examine this potential link between physical fitness and mental fitness for people with Down syndrome.

The U.S. Federal Trade Commission (FTC) formed a multinational working group to evaluate pharmaceutical mergers.